Search

everythinglearnresearchcommunity

for

Search:↓

A monoclonal antibody clinical trial for potential hair loss treatments in Victoria, Australia and the discussion of their efficacy. People shared information about similar drugs already on the market, speculated about potential side effects, and discussed how to spread the word about the trial.

A 21-year-old male suffering from male pattern baldness is using topical finasteride and minoxidil, and oral minoxidil. His bloodwork shows normal DHT levels and slightly high testosterone, leading to discussions about the role of DHT sensitivity in hair loss, the potential impact of finasteride on his DHT levels, and the suggestion to proceed with oral finasteride due to his high testosterone.

Copper peptides, specifically GHK-Cu, are discussed as a potential addition to hair loss treatments, possibly working synergistically with Minoxidil to convert vellus hair into terminal hair. The effectiveness and credibility of copper peptides are questioned due to the lack of widespread discussion and potential conflict of interest from the product's creator.

The conversation discusses skepticism about new hair loss treatments, with many users expressing doubt about the effectiveness and availability of future solutions. Current treatments like minoxidil, finasteride, and hair transplants are mentioned as reliable options.

The user is experiencing hair loss with possible causes including chronic telogen effluvium, diffuse alopecia areata, and androgenic alopecia. They have tried treatments like Nizoral shampoo, minoxidil, and finasteride, and are considering a biopsy for further clarity.

The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

Experimenting with the effects of creatine and finasteride on DHT levels, as well as a discussion regarding the potential link between creatine supplementation and hair loss.

Hair loss treatments, specifically Pyrilutamide and Minoxidil/Finasteride/RU58841. Participants discussed their experiences with them and the results they have seen so far.

Dr. Bloxham's trial is testing verteporfin on hair transplant patients to see if it can improve hair regrowth in treated areas. People are discussing the potential for follicle regeneration, expected results timeline, and concerns about side effects like cancer.

Verteporfin may improve hair transplant outcomes and reduce scarring, potentially allowing patients to avoid finasteride. Dr. Barghouthi seeks collaborations, volunteers, and financial support for research on verteporfin.org.

PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.

The user has been using minoxidil, finasteride, a laser cap, and ketoconazole shampoo for hair loss without success and is seeking advice on further tests or treatments. They have a family history of hair loss and have not yet undergone dermatologist or trichology tests.

A case study that suggests verteporfin may be able to help regrow donor hairs after FUE extraction, and the potential implications of this result. Treatments discussed include Minoxidil, Finasteride, and RU58841.

The conversation discusses the anticipated release of GT20029, with some users expressing skepticism about its availability. It also mentions the use of treatments like Minoxidil, finasteride, RU58841, and dutasteride for hair loss.

A user shared their experience with hair loss treatments, finding success with a topical hair serum containing GHK Cu and AHK Cu, which reduced shedding. They avoided hormonal treatments like finasteride and minoxidil, and noted skepticism from others about non-traditional treatments.

The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

A 25-year-old male experienced noticeable temple regrowth using 1mg finasteride, 2.5mg oral minoxidil, and 2mg GHK-Cu over three months. The user is pleased with the progress, especially on the left temple.

The user experimented with finasteride to reduce hair loss and plans to test if creatine affects DHT levels while on finasteride. Initial results showed low DHT levels, indicating finasteride's effectiveness, with further tests planned for creatine's impact.

The conversation is about a user assessing their hair loss as Norwood 1.5 and discussing their use of oral minoxidil and finasteride for 2.5 years, which improved their hair density. They are content with their current progress but hope to reach Norwood 1.

A 25-year-old with AGA experienced hair thinning and dandruff, stabilized with topical finasteride and minoxidil but saw minimal regrowth. They seek advice on styling and consider oral minoxidil and microneedling for denser hair.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly suggests the creation of a new chemical called RU99999.

The conversation discusses the molecular structures of compounds that reduce DHT levels, including finasteride and Ashwagandha. It explores the potential of using Ashwagandha topically as a 5a reductase inhibitor.

Injections of follistatin and growth factors can improve hair growth. Specific treatments discussed include Minoxidil, finasteride, and RU58841.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

PP405 is a potential hair loss treatment that may reactivate dormant hair follicles, with Phase 3 trials expected. Some users are cautious, suggesting using finasteride in the meantime, while others are skeptical about PP405's effectiveness.

RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.

J. Hewitt plans to trial hair multiplication in Japan by the end of 2019. The technique was developed by German researchers at the University of Berlin and formed the company "TissUse."

The conclusion of the conversation is that the user, djamezz, has experienced significant regrowth and improved density in their hairline by using treatments such as RU (RU58841), dut (dutasteride), and Inkey's Caffeine Scalp treatment. They are satisfied with their progress and do not plan to cut off their hair.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.